论文部分内容阅读
目的 探讨联合检测c-erbB-2,p53,CEA的表达对指导临床治疗及预后价值。方法 应用免疫组化技术对我院165例结肠癌结合临床病理进行分析。结果 c- erbB- 2, p53, CEA的表达分别为55 .15%,58 18%,78. 7%。结论 c-erbB-2,p53与临床结肠癌的形态大小、淋巴结转移以及分化程度有关,与组织学类型似乎有关,有待进一步探讨;c-erbB-2,p53,CEA联合阳性表达对临床治疗及预后有一定的指导意义。
Objective To investigate the clinical value of combined detection of c-erbB-2, p53 and CEA in clinical treatment and prognosis. Methods The clinical and pathological features of 165 cases of colon cancer in our hospital were analyzed by immunohistochemistry. Results The expressions of c-erbB-2, p53 and CEA were 55.15%, 58.18% and 78.7% respectively. Conclusions The expression of c-erbB-2 and p53 is related to the size, lymph node metastasis and differentiation of colon cancer, which may be related to the histological type. The relationship between c-erbB-2, p53 and CEA Prognosis has some guiding significance.